Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database
Permanent link to Research Commons versionhttps://hdl.handle.net/10289/15666
Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen. Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.
Asian Medical Press Limited
© 2022 Asia-Pacific Journal of Oncology. This work is licensed under a CC BY 4.0 licence.